Navigation Links
Transcept Pharmaceuticals to Host Conference Call to Discuss Preliminary Analysis of Intermezzo® Highway Driving Study
Date:10/18/2010

Transcept Pharmaceuticals to Host Conference Call to Discuss Preliminary Analysis of Intermezzo®... -- POINT RICHMOND, Calif., Oct. 18 /PRNewswire-FirstCall/ --


Advanced Search Search

  
Close
  1. Send a release
  2. Member sign in
  3. Become a member
  4. For journalists
  5. Global sites
PR Newswire: news distribution, targeting and monitoring
  1. Products & Services
  2. Knowledge Center
  3. Browse News Releases
  4. Contact PR Newswire
Health Care & Hospitals, Medical Pharmaceuticals, Pharmaceuticals Click to view news release full screen  

Transcept Pharmaceuticals to Host Conference Call to Discuss Preliminary Analysis of Intermezzo® Highway Driving Study

   

Call Scheduled for Tuesday, October 19, 2010 at 8:00 a.m. EDT

POINT RICHMOND, Calif., Oct. 18 /PRNewswire-FirstCall/ -- Transcept Pharmaceuticals, Inc. (Nasdaq: TSPT), a specialty pharmaceutical company focused on the development and commercialization of proprietary products that address important therapeutic needs in the field of neuroscience, today announced that it will host a conference call to discuss the recently announced preliminary analysis of the Intermezzo® highway driving study.Conference Call Information Date: Tuesday, October 19, 2010Time: 8:00 a.m. ETDial-in (U.S.): 877-638-4558Dial-in (International): 914-495-8537A simultaneous web cast of the conference call will be available on the Investors section of the Transcept website at www.transcept.com. A replay of the call will be available on the website shortly after the conclusion of the call until November 23, 2010.

A telephone replay of the conference call will be available shortly after the conclusion of the call until end of business October 23, 2010. The replay telephone numbers are 800-642-1687 (U.S.) and 706-645-9291 (International), replay passcode: 19398284.

About TransceptTranscept Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development and commercialization of proprietary products that address important therapeutic needs in the field of neuroscience. The most advanced Transcept product candidate is Intermezzo® (zolpidem tartrate sublingual tablet), for which a New Drug Application (NDA) was submitted to the U.S. Food and Drug Administration (FDA) in September 2008 seeking approval as a prescription sleep aid for use in the middle of the night at the time a patient awakens and has difficulty returning to sleep. In October 2009, Transcept received a Complete Response Letter from the FDA on the Intermezzo® NDA and is working to respond to issues raised in the letter. Transcept and Purdue Pharmaceutical Products L.P. have entered into a collaboration agreement for the development and commercialization of Intermezzo® in the United States.  For further information, please visit the Transcept website at: www.transcept.com.

Contact:Transcept Pharmaceuticals, Inc.Greg MannDirector, Corporate Communications(510) 215-3567gmann@transcept.com
'/>"/>

SOURCE Transcept Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Transcept Pharmaceuticals to Present at Newsmakers in the Biotech Industry Conference
2. Transcept Pharmaceuticals to Present at BIO Investor Forum
3. Transcept Pharmaceuticals to Present at UBS Global Life Sciences Conference
4. Transcept Pharmaceuticals to Present at Rodman & Renshaw and Stifel Nicolaus Investor Conferences in September 2010
5. Transcept Pharmaceuticals Receives Notice of Allowance for Second U.S. Patent Application Covering Intermezzo(R)
6. Transcept Pharmaceuticals Scheduled to Meet With FDA to Discuss Intermezzo(R) Complete Response Letter
7. Transcept Pharmaceuticals Reports Third Quarter 2009 Financial Results
8. Transcept Pharmaceuticals to Present at Lazard Capital Markets Healthcare Conference on November 17
9. Transcept Pharmaceuticals to Report Third Quarter 2009 Results and Host Conference Call on November 12
10. Transcept Pharmaceuticals Receives Complete Response Letter from FDA on Intermezzo(R) New Drug Application
11. Transcept Pharmaceuticals to Report First Quarter 2009 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... March 29, 2017  Maxor National Pharmacy Services, LLC ... it has named Leah Bailey as General ... of the company. With more than 13 ... 8 years focused on health care, Bailey joins the ... at Prime, Bailey advised the PBM, Specialty, and Mail ...
(Date:3/29/2017)... Pharmaceutical Care Management Association (PCMA) today released the following ... spending: According to the ... amount spent out-of-pocket for drugs continues to decline, projected ... from 23% in 2006. Rising drug ... Health plans don,t have unlimited funds to pay first ...
(Date:3/29/2017)... Research and Markets has announced the addition ... report to their offering. ... The ablation device global market is expected to ... 2023. Ablation is the minimally invasive therapeutic tissue ... or diseased tissue removal, to the removal of abnormally conducting cardiac ...
Breaking Medicine Technology:
(Date:3/29/2017)... ... March 29, 2017 , ... During the last week of March, Chad Kawa, ... eligible individuals in the local community. , Colon cancer is the second leading ... colon cancer while it is small, confined and easier to treat. If you are ...
(Date:3/29/2017)... ... 2017 , ... Full Contact K9, an Atlanta-based dog services provider, has recently ... assists dog owners in creating legally-enforceable pet trusts for their canine companions. , ... to protect their new companion. Says Evan Dunbar, CEO of Full Contact K9, “When ...
(Date:3/29/2017)... FL (PRWEB) , ... March 30, 2017 , ... Sublime ... the "Spice of Life" or "Wonder Spice", it has been used for thousands of ... in the East," says Heshelow, author of " Turmeric: How to Use it For ...
(Date:3/29/2017)... BC (PRWEB) , ... March 29, 2017 , ... ... makeover services with or without a referral to new patients from Burnaby, BC. ... or other full mouth reconstruction services, can see the esteemed team at ...
(Date:3/29/2017)... ANN ARBOR, Mich. (PRWEB) , ... ... ... Global Retailer and Manufacturer Alliance (GRMA) is growing as it continues developing ... the dietary supplement industry. The organization, which plans to publish the first ...
Breaking Medicine News(10 mins):